Home » Newsletters » The Carlat Child Psychiatry Report

The Carlat Child Psychiatry Report

Psychosis in Children and Adolescent (April/May/June) | 2025

View Archived Issues

Learning Objectives, Psychosis in Children and Adolescents, CCPR, April/May/June 2025

April 1, 2025

After reading these articles, you should be able to…

Note from the Editor In Chief, CCPR, April/May/June 2025

April 1, 2025

Joshua Feder, MD

Welcome back to CCPR! We interview Dr. Kristin Cadenhead on psychotic-like experiences, Dr. David Beckman on substance-related psychosis, and Julie Dopheide, PharmD, on metabolic-sparing antipsychotics. We also cover selective mutism, cardiovascular effects of ADHD medications, and a caution from Danielle Reynolds, MS IV, on Delta-8 – warn your patients!

Selective Mutism: Helping Kids Find Their Voice

April 1, 2025

Mariel Zeccola, APRN, PhD

Selective mutism (SM) in children can create tremendous frustration, often resulting in harsh reactions from parents or teachers. This clinical update from our own Dr. Mariel Zeccola will help you differentiate SM from co-occurring anxiety and other conditions and offer a path to treatment with therapy and, when needed, medication.

Sorting Out Psychotic-Like Experiences in Children and Teens

April 1, 2025

Kristin Cadenhead, MD

What are psychotic-like experiences (PLE) in children and teens, and what is the prognosis for those who have them? Should we treat immediately with antipsychotics? Watch and wait? Our interview with Dr. Kristin Cadenhead gives you the guidance you need to assess and manage PLE.

Managing Substance-Induced Psychosis in Teens

April 1, 2025

David Beckmann, MD, MPH

How do we decide whether a psychotic condition is due to substance use or a primary condition, and how does that affect our care of the patient? We spoke with Dr. David Beckmann about substance-induced psychosis in teens to help us outline the workup and approach to this common clinical conundrum.

Antipsychotics and Weight Gain in Younger Patients

April 1, 2025

Julie Ann Dopheide, PharmD, BCPP, FASHP

Julie Ann Dopheide, PharmD, BCPP, FASHP, Professor of Clinical Pharmacy, Psychiatry and the Behavioral Sciences, USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences and Keck School of Medicine, University of Southern California, Los Angeles, CA.
Dr. Dopheide has no financial relationships with companies related to this material.

Long-Term Cardiovascular Risks of ADHD Medications: A Closer Look

April 1, 2025

Joshua Feder, MD

We know that stimulant medications for ADHD can reduce chronic health conditions and extend healthy years for patients. But are there cardiovascular risks from these or non-stimulant medications used for ADHD? In this research update, we review a study that helps clarify the risks of long term use in youth and adults.